Compare Ascendis Pharma A/S (ASND) vs J B Hunt Transport Services Inc (JBHT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs J B Hunt Transport Services Inc — how do they compare? Ascendis Pharma A/S trades at $256.5 (market cap $16.67B), while J B Hunt Transport Services Inc trades at $265.38 (market cap $24.92B). The key difference: J B Hunt Transport Services Inc is the larger of the two by market cap, and J B Hunt Transport Services Inc pays a 0.68% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | JBHT | |
|---|---|---|
Market Cap | $16.67B | $24.92B |
Sector | Health | Industrials |
52-Week High | $277.18 | $298.41 |
52-Week Low | $189.74 | $130.65 |
Enterprise Value | $17.04B | $26.06B |
Dividend Yield | — | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.46, showing minimal daily movement (-0.06%). The stock maintains a bullish technical outlook with strong analyst support (92% buy ratings) and a consensus price target of $309.75, representing 21% upside potential. Recent developments include positive clinical trial updates for TransCon CNP in achondroplasia and inclusion in multiple Russell indexes, signaling growing institutional recognition. Revenue growth has been robust, increasing from $51M in 2022 to $720M in 2025, though the company remains unprofitable with a net loss of $228M in 2025.
ASND presents a growth investment opportunity with multiple product catalysts and improving financial trajectory, though significant risks remain. The company's premium valuation (P/E 29.05, P/S 15.68) reflects high growth expectations, while negative shareholder equity and substantial debt require careful monitoring. Positive cash flow generation since 2024 and upcoming regulatory milestones provide potential upside, but execution risks and clinical trial outcomes could impact shareholder value.
JBHT trades at $275.86, up 3.65% today, with a bearish technical signal but strong analyst support. Recent quarters show earnings beats, with Q3 2026 expected at $2.12 EPS. Revenue is projected to grow to $12.7B in 2026, with a net income margin of 5.31%. The company maintains solid profitability metrics, including an 18.45% ROE, and announced a $0.45 dividend payable in August 2026.
The outlook is mixed; strong fundamentals and a $299.82 consensus price target suggest upside, but bearish technicals and competitive pressures pose risks. Investors should weigh earnings consistency against market volatility and sector headwinds for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →
